[시장보고서]인공관절 감염증 치료 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

인공관절 감염증 치료 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Prosthetic Joint Infections Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1631377

리서치사 : Persistence Market Research

발행일 : 2025년 01월

페이지 정보 : 영문 227 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,411,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,823,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,604,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 인공관절 감염증 치료 시장 규모는 2025년에 1,154억 달러에 달할 것으로 보이며, 2025-2032년의 예측 기간에 5.0%의 연평균 복합 성장률(CAGR)로 확대되어 2032년에는 1,621억 달러에 달할 것으로 예측됩니다.

인공관절 감염증(PJI) 치료에는 인공관절 치환술에 수반되는 감염증에 대처하는 것을 목적으로 한 치료법이나 항생제가 포함됩니다. 이 시장을 견인하고 있는 것은 인공 관절 치환술의 건수 증가, 당뇨병이나 관절염 등의 만성 질환의 유병률의 상승, 진단·치료 기술의 진보 등입니다. 의약품과 병용 요법의 개발이 시장의 성장을 가속하고 있습니다.

인구 고령화에 의한 인공관절 치환술의 건수 증가, 비만과 변형성 관절증의 유병률의 상승 등, 여러 요인이 세계의 인공관절 감염 치료 시장의 성장을 뒷받침하고 있습니다. 진단 기술 진보로 PJI의 조기 발견률이 향상되어 치료 수요가 높아지고 있습니다.

인공 관절 감염 치료 시장은 특히 새로운 항생제와 병용 요법의 연구 개발이 진행되고 있기 때문에 큰 성장 기회를 가져오고 있습니다. 혁신적인 치료 솔루션을 개발하기 위한 제약 기업 제휴는 추가 성장 가능성을 이끌어낼 것으로 기대됩니다. 인프라 투자가 증가하고 PJI 치료에 대한 인식이 높아지고 있는 신흥국에서의 확대도 유망한 성장의 길을 제공합니다. 치료 충고가 강화되어 시장 확대에 기여할 수 있습니다.

본 보고서에서는 세계의 인공관절 감염증 치료 시장에 대해 조사했으며, 약제별, 감염증별, 별도, 병원체별, 투여경로별, 유통채널별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

경쟁 대시보드
주요 개발 분석
주요 진출기업에 의한 브랜딩 및 프로모션 전략
경쟁의 상세
- Pfizer Inc.
- Novartis AG
- Mylan NV
- Teva Pharmaceuticals
- Merck & Co.
- Eli Lilly & Company
- AstraZeneca plc.
- Lupin Limited
- Dr Reddys Laboratories
- Aurobindo Pharma Ltd
- GSK plc.
- Sun Pharmaceutical Industries Ltd.
- Cipla ltd.

제22장 사용된 전제조건과 약어

제23장 조사 방법

JHS

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Prosthetic Joint Infection (PJI) Treatment Market, providing an in-depth analysis of key market dynamics, including drivers, emerging trends, opportunities, and challenges. This report offers valuable insights into the market landscape, helping stakeholders make informed decisions about growth strategies.

Key Insights:

Prosthetic Joint Infection Treatment Market Size (2025E): USD 115.4 Bn
Projected Market Value (2032F): USD 162.1 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 5.0%

Prosthetic Joint Infection Treatment Market - Report Scope:

Prosthetic Joint Infection (PJI) treatment involves therapies and antibiotics aimed at combating infections associated with joint replacement surgeries. PJI is a serious complication often caused by pathogens such as Staphylococcus aureus or Candida species. This market is driven by the rising number of joint replacement surgeries, increasing prevalence of chronic conditions such as diabetes and arthritis, and advancements in diagnostic and treatment techniques. Furthermore, the development of innovative drugs and combination therapies is fueling market growth.

Market Growth Drivers:

Several factors drive the growth of the global Prosthetic Joint Infection Treatment Market, including the rising number of joint replacement surgeries due to an aging population and increased prevalence of obesity and osteoarthritis. Technological advancements in diagnostics, such as PCR-based testing, have improved early detection rates of PJI, thus driving demand for treatment. Increasing awareness about hospital-acquired infections and the development of targeted therapies and advanced drug delivery systems are further bolstering market growth.

Market Restraints:

Despite its promising growth, the PJI treatment market faces challenges such as high treatment costs and limited availability of effective therapies in low-income regions. Moreover, the growing incidence of antibiotic resistance poses a significant barrier to effective treatment, necessitating the development of new antibiotics and alternative therapeutic approaches. Regulatory hurdles in approving new drugs and therapies for PJI also act as market constraints.

Market Opportunities:

The Prosthetic Joint Infection Treatment Market presents substantial growth opportunities, particularly with the ongoing research and development of new antibiotics and combination therapies. Partnerships between pharmaceutical companies and healthcare institutions to develop innovative treatment solutions are expected to unlock further growth potential. Expansion in emerging economies with increasing healthcare infrastructure investment and rising awareness of PJI treatments also provides a promising growth avenue. The integration of AI-driven diagnostic tools and telemedicine platforms could enhance early diagnosis and treatment adherence, contributing to market expansion.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Prosthetic Joint Infection Treatment Market?
Which drug classes and pathogens dominate the market?
How are technological advancements shaping the competitive landscape of the market?
Who are the key players, and what strategies are they employing to stay competitive?
What are the emerging trends and future prospects in the PJI treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global Prosthetic Joint Infection Treatment Market, including Pfizer Inc., Novartis AG, and Mylan N.V., are focusing on R&D initiatives, strategic collaborations, and product innovations to strengthen their market positions. Companies are actively investing in developing novel antibiotics to combat drug-resistant strains and enhance treatment outcomes. Expansion into emerging markets, along with partnerships with hospitals and diagnostic centers, is a key strategy for market penetration. Emphasis on affordability, safety, and compliance with regulatory standards ensures long-term success for these players in the competitive landscape.

Key Companies Profiled:

Pfizer Inc.
Novartis AG
Mylan N.V.
Teva Pharmaceuticals
Merck & Co.
Eli Lilly & Company
AstraZeneca PLC
Lupin Limited
Dr. Reddy's Laboratories
Aurobindo Pharma Ltd.
GSK PLC
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.

Prosthetic Joint Infection Treatment Industry Research by Category:

By Drug:

Aminoglycosides
Glycopeptides
Rifamycin
Lincosamide
Penicillin
Other Antibiotics

By Infection:

Pre-operative Infection
Post-operative Infection

By Route of Administration:

Oral
Intravenous

By Pathogen:

Staphylococcus Aureus
Coagulase-negative Staphylococcus
Candida Species
Enterococcus Species
Other Pathogens

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Value Added Insights

4.1. Product Adoption Analysis
4.2. Product USPs/Features Analysis, By Brands
4.3. Regulatory Landscape, By Country
4.4. Recent Product Approval/Launches
4.5. Disease Epidemiology
4.6. Porter's Analysis
4.7. PESTLE Analysis
4.8. Value Chain Analysis
4.9. Unmet Needs

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global Healthcare Expenditure Outlook
- 5.1.2. Global Pharmaceutical Market Outlook
- 5.1.3. Global Surgical Site Infection Control Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Rising Rate of Joint Surgery
- 5.2.2. Increase in Research and Development
- 5.2.3. Strategic Collaborations among players
- 5.2.4. Cost of Product
- 5.2.5. Business Expansions
- 5.2.6. Frequency of Product Approval
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019 - 2024 and Forecast, 2025 - 2032

6.1. Historical Market Value (US$ Bn) Analysis, 2019 - 2024
6.2. Current and Future Market Size (US$ Bn) Projections, 2025 - 2032
- 6.2.1. Y-o-Y Growth Trend Analysis
- 6.2.2. Absolute $ Opportunity Analysis
6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Drug

7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019 - 2024
7.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2025 - 2032
- 7.3.1. Aminoglycosides
- 7.3.2. Glycopeptides
- 7.3.3. Rifamycin
- 7.3.4. Lincosamide
- 7.3.5. Penicillin
- 7.3.6. Other Antibiotics
7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Infection

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Infection, 2019 - 2024
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Infection, 2025 - 2032
- 8.3.1. Pre-operative Infection
- 8.3.2. Post-operative Infection
8.4. Market Attractiveness Analysis By Infection

9. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Pathogen

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis By Pathogen, 2019 - 2024
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Pathogen, 2025 - 2032
- 9.3.1. Staphylococcus aureus
- 9.3.2. Coagulase-negative Staphylococcus
- 9.3.3. Candida species
- 9.3.4. Enterococcus species
- 9.3.5. Other Pathogens
9.4. Market Attractiveness Analysis By Pathogen

10. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Route of Administration

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2019 - 2024
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2025 - 2032
- 10.3.1. Oral
- 10.3.2. Intravenous
10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Distribution Channel

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019 - 2024
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2025 - 2032
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies
- 11.3.3. Drug Stores
- 11.3.4. Online Sales
11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, by Region

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019 - 2024
12.3. Current and Future Market Size (US$ Bn) Analysis Forecast By Region, 2025 - 2032
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. South Asia
- 12.3.5. East Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019 - 2024 and Forecast 2025 - 2032

13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 13.3.1. By Country
  - 13.3.1.1. United States
  - 13.3.1.2. Canada
- 13.3.2. By Drug
- 13.3.3. By Infection
- 13.3.4. By Pathogen
- 13.3.5. By Route of Administration
- 13.3.6. By Distribution Channel
13.4. Market Attractiveness Analysis By Region
- 13.4.1. By Country
- 13.4.2. By Drug
- 13.4.3. By Infection
- 13.4.4. By Pathogen
- 13.4.5. By Route of Administration
- 13.4.6. By Distribution Channel
13.5. Market trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. United States Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug
    - 13.8.1.2.2. By Infection
    - 13.8.1.2.3. By Pathogen
    - 13.8.1.2.4. By Route of Administration
    - 13.8.1.2.5. By Distribution Channel
- 13.8.2. Canada Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug
    - 13.8.2.2.2. By Infection
    - 13.8.2.2.3. By Pathogen
    - 13.8.2.2.4. By Route of Administration
    - 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019 - 2024 and Forecast 2025 - 2032

14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 14.3.1. By Country
  - 14.3.1.1. Brazil
  - 14.3.1.2. Mexico
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug
- 14.3.3. By Infection
- 14.3.4. By Pathogen
- 14.3.5. By Route of Administration
- 14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis By Region
- 14.4.1. By Country
- 14.4.2. By Drug
- 14.4.3. By Infection
- 14.4.4. By Pathogen
- 14.4.5. By Route of Administration
- 14.4.6. By Distribution Channel
14.5. Market trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Brazil Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug
    - 14.8.1.2.2. By Infection
    - 14.8.1.2.3. By Pathogen
    - 14.8.1.2.4. By Route of Administration
    - 14.8.1.2.5. By Distribution Channel
- 14.8.2. Mexico Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug
    - 14.8.2.2.2. By Infection
    - 14.8.2.2.3. By Pathogen
    - 14.8.2.2.4. By Route of Administration
    - 14.8.2.2.5. By Distribution Channel
- 14.8.3. Argentina Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug
    - 14.8.3.2.2. By Infection
    - 14.8.3.2.3. By Pathogen
    - 14.8.3.2.4. By Route of Administration
    - 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019 - 2024 and Forecast 2025 - 2032

15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. France
  - 15.3.1.3. Spain
  - 15.3.1.4. Russia
  - 15.3.1.5. Italy
  - 15.3.1.6. BENELUX
  - 15.3.1.7. United Kingdom
  - 15.3.1.8. Rest of Europe
- 15.3.2. By Drug
- 15.3.3. By Infection
- 15.3.4. By Pathogen
- 15.3.5. By Route of Administration
- 15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis By Region
- 15.4.1. By Country
- 15.4.2. By Drug
- 15.4.3. By Infection
- 15.4.4. By Pathogen
- 15.4.5. By Route of Administration
- 15.4.6. By Distribution Channel
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug
    - 15.8.1.2.2. By Infection
    - 15.8.1.2.3. By Pathogen
    - 15.8.1.2.4. By Route of Administration
    - 15.8.1.2.5. By Distribution Channel
- 15.8.2. France Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug
    - 15.8.2.2.2. By Infection
    - 15.8.2.2.3. By Pathogen
    - 15.8.2.2.4. By Route of Administration
    - 15.8.2.2.5. By Distribution Channel
- 15.8.3. Spain Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug
    - 15.8.3.2.2. By Infection
    - 15.8.3.2.3. By Pathogen
    - 15.8.3.2.4. By Route of Administration
    - 15.8.3.2.5. By Distribution Channel
- 15.8.4. Russia Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Drug
    - 15.8.4.2.2. By Infection
    - 15.8.4.2.3. By Pathogen
    - 15.8.4.2.4. By Route of Administration
    - 15.8.4.2.5. By Distribution Channel
- 15.8.5. Italy Market Analysis
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.5.2.1. By Drug
    - 15.8.5.2.2. By Infection
    - 15.8.5.2.3. By Pathogen
    - 15.8.5.2.4. By Route of Administration
    - 15.8.5.2.5. By Distribution Channel
- 15.8.6. BENELUX Market Analysis
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.6.2.1. By Drug
    - 15.8.6.2.2. By Infection
    - 15.8.6.2.3. By Pathogen
    - 15.8.6.2.4. By Route of Administration
    - 15.8.6.2.5. By Distribution Channel
- 15.8.7. United Kingdom Market Analysis
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.7.2.1. By Drug
    - 15.8.7.2.2. By Infection
    - 15.8.7.2.3. By Pathogen
    - 15.8.7.2.4. By Route of Administration
    - 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019 - 2024 and Forecast 2025 - 2032

16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 16.3.1. By Country
  - 16.3.1.1. China
  - 16.3.1.2. Japan
  - 16.3.1.3. South Korea
- 16.3.2. By Drug
- 16.3.3. By Infection
- 16.3.4. By Pathogen
- 16.3.5. By Route of Administration
- 16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis By Region
- 16.4.1. By Country
- 16.4.2. By Drug
- 16.4.3. By Infection
- 16.4.4. By Pathogen
- 16.4.5. By Route of Administration
- 16.4.6. By Distribution Channel
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. China Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug
    - 16.8.1.2.2. By Infection
    - 16.8.1.2.3. By Pathogen
    - 16.8.1.2.4. By Route of Administration
    - 16.8.1.2.5. By Distribution Channel
- 16.8.2. Japan Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug
    - 16.8.2.2.2. By Infection
    - 16.8.2.2.3. By Pathogen
    - 16.8.2.2.4. By Route of Administration
    - 16.8.2.2.5. By Distribution Channel
- 16.8.3. South Korea Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Drug
    - 16.8.3.2.2. By Infection
    - 16.8.3.2.3. By Pathogen
    - 16.8.3.2.4. By Route of Administration
    - 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019 - 2024 and Forecast 2025 - 2032

17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 17.3.1. By Country
  - 17.3.1.1. India
  - 17.3.1.2. Indonesia
  - 17.3.1.3. Thailand
  - 17.3.1.4. Philippines
  - 17.3.1.5. Malaysia
  - 17.3.1.6. Vietnam
  - 17.3.1.7. Rest of South Asia
- 17.3.2. By Drug
- 17.3.3. By Infection
- 17.3.4. By Pathogen
- 17.3.5. By Route of Administration
- 17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis By Region
- 17.4.1. By Country
- 17.4.2. By Drug
- 17.4.3. By Infection
- 17.4.4. By Pathogen
- 17.4.5. By Route of Administration
- 17.4.6. By Distribution Channel
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. India Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug
    - 17.8.1.2.2. By Infection
    - 17.8.1.2.3. By Pathogen
    - 17.8.1.2.4. By Route of Administration
    - 17.8.1.2.5. By Distribution Channel
- 17.8.2. Indonesia Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug
    - 17.8.2.2.2. By Infection
    - 17.8.2.2.3. By Pathogen
    - 17.8.2.2.4. By Route of Administration
    - 17.8.2.2.5. By Distribution Channel
- 17.8.3. Thailand Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Drug
    - 17.8.3.2.2. By Infection
    - 17.8.3.2.3. By Pathogen
    - 17.8.3.2.4. By Route of Administration
    - 17.8.3.2.5. By Distribution Channel
- 17.8.4. Philippines Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Drug
    - 17.8.4.2.2. By Infection
    - 17.8.4.2.3. By Pathogen
    - 17.8.4.2.4. By Route of Administration
    - 17.8.4.2.5. By Distribution Channel
- 17.8.5. Malaysia Market Analysis
  - 17.8.5.1. Introduction
  - 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.5.2.1. By Drug
    - 17.8.5.2.2. By Infection
    - 17.8.5.2.3. By Pathogen
    - 17.8.5.2.4. By Route of Administration
    - 17.8.5.2.5. By Distribution Channel
- 17.8.6. Vietnam Market Analysis
  - 17.8.6.1. Introduction
  - 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.6.2.1. By Drug
    - 17.8.6.2.2. By Infection
    - 17.8.6.2.3. By Pathogen
    - 17.8.6.2.4. By Route of Administration
    - 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019 - 2024 and Forecast 2025 - 2032

18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Drug
- 18.3.3. By Infection
- 18.3.4. By Pathogen
- 18.3.5. By Route of Administration
- 18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis By Region
- 18.4.1. By Country
- 18.4.2. By Drug
- 18.4.3. By Infection
- 18.4.4. By Pathogen
- 18.4.5. By Route of Administration
- 18.4.6. By Distribution Channel
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Drug
    - 18.8.1.2.2. By Infection
    - 18.8.1.2.3. By Pathogen
    - 18.8.1.2.4. By Route of Administration
    - 18.8.1.2.5. By Distribution Channel
- 18.8.2. New Zealand Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Drug
    - 18.8.2.2.2. By Infection
    - 18.8.2.2.3. By Pathogen
    - 18.8.2.2.4. By Route of Administration
    - 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019 - 2024 and Forecast 2025 - 2032

19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkiye
  - 19.3.1.3. Egypt
  - 19.3.1.4. Israel
  - 19.3.1.5. South Africa
  - 19.3.1.6. Northern Africa
  - 19.3.1.7. Rest of Middle East and Africa
- 19.3.2. By Drug
- 19.3.3. By Infection
- 19.3.4. By Pathogen
- 19.3.5. By Route of Administration
- 19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis By Region
- 19.4.1. By Country
- 19.4.2. By Drug
- 19.4.3. By Infection
- 19.4.4. By Pathogen
- 19.4.5. By Route of Administration
- 19.4.6. By Distribution Channel
19.5. Market trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Market Analysis
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.1.2.1. By Drug
    - 19.8.1.2.2. By Infection
    - 19.8.1.2.3. By Pathogen
    - 19.8.1.2.4. By Route of Administration
    - 19.8.1.2.5. By Distribution Channel
- 19.8.2. Turkiye Market Analysis
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.2.2.1. By Drug
    - 19.8.2.2.2. By Infection
    - 19.8.2.2.3. By Pathogen
    - 19.8.2.2.4. By Route of Administration
    - 19.8.2.2.5. By Distribution Channel
- 19.8.3. Egypt Market Analysis
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.3.2.1. By Drug
    - 19.8.3.2.2. By Infection
    - 19.8.3.2.3. By Pathogen
    - 19.8.3.2.4. By Route of Administration
    - 19.8.3.2.5. By Distribution Channel
- 19.8.4. Israel Market Analysis
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.4.2.1. By Drug
    - 19.8.4.2.2. By Infection
    - 19.8.4.2.3. By Pathogen
    - 19.8.4.2.4. By Route of Administration
    - 19.8.4.2.5. By Distribution Channel
- 19.8.5. South Africa Market Analysis
  - 19.8.5.1. Introduction
  - 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.5.2.1. By Drug
    - 19.8.5.2.2. By Infection
    - 19.8.5.2.3. By Pathogen
    - 19.8.5.2.4. By Route of Administration
    - 19.8.5.2.5. By Distribution Channel
- 19.8.6. Northern Africa Market Analysis
  - 19.8.6.1. Introduction
  - 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.6.2.1. By Drug
    - 19.8.6.2.2. By Infection
    - 19.8.6.2.3. By Pathogen
    - 19.8.6.2.4. By Route of Administration
    - 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
- 20.3.1. Regional Footprint of Players
- 20.3.2. Product Footprint of Players
- 20.3.3. Channel Footprint of Players

21. Competition Analysis

21.1. Competition Dashboard
21.2. Key Development Analysis
21.3. Branding and Promotional Strategies, By Key Players
21.4. Competition Deep Dive
- 21.4.1. Pfizer Inc.
  - 21.4.1.1. Overview
  - 21.4.1.2. Product Portfolio
  - 21.4.1.3. Key Financials
  - 21.4.1.4. Sales Footprint
  - 21.4.1.5. SWOT Analysis
  - 21.4.1.6. Strategy Overview
    - 21.4.1.6.1. Marketing Strategies
    - 21.4.1.6.2. Channel Strategies
    - 21.4.1.6.3. Product Strategies
- 21.4.2. Novartis AG
  - 21.4.2.1. Overview
  - 21.4.2.2. Product Portfolio
  - 21.4.2.3. Key Financials
  - 21.4.2.4. Sales Footprint
  - 21.4.2.5. SWOT Analysis
  - 21.4.2.6. Strategy Overview
    - 21.4.2.6.1. Marketing Strategies
    - 21.4.2.6.2. Channel Strategies
    - 21.4.2.6.3. Product Strategies
- 21.4.3. Mylan N.V.
  - 21.4.3.1. Overview
  - 21.4.3.2. Product Portfolio
  - 21.4.3.3. Key Financials
  - 21.4.3.4. Sales Footprint
  - 21.4.3.5. SWOT Analysis
  - 21.4.3.6. Strategy Overview
    - 21.4.3.6.1. Marketing Strategies
    - 21.4.3.6.2. Channel Strategies
    - 21.4.3.6.3. Product Strategies
- 21.4.4. Teva Pharmaceuticals
  - 21.4.4.1. Overview
  - 21.4.4.2. Product Portfolio
  - 21.4.4.3. Key Financials
  - 21.4.4.4. Sales Footprint
  - 21.4.4.5. SWOT Analysis
  - 21.4.4.6. Strategy Overview
    - 21.4.4.6.1. Marketing Strategies
    - 21.4.4.6.2. Channel Strategies
    - 21.4.4.6.3. Product Strategies
- 21.4.5. Merck & Co.
  - 21.4.5.1. Overview
  - 21.4.5.2. Product Portfolio
  - 21.4.5.3. Key Financials
  - 21.4.5.4. Sales Footprint
  - 21.4.5.5. SWOT Analysis
  - 21.4.5.6. Strategy Overview
    - 21.4.5.6.1. Marketing Strategies
    - 21.4.5.6.2. Channel Strategies
    - 21.4.5.6.3. Product Strategies
- 21.4.6. Eli Lilly & Company
  - 21.4.6.1. Overview
  - 21.4.6.2. Product Portfolio
  - 21.4.6.3. Key Financials
  - 21.4.6.4. Sales Footprint
  - 21.4.6.5. SWOT Analysis
  - 21.4.6.6. Strategy Overview
    - 21.4.6.6.1. Marketing Strategies
    - 21.4.6.6.2. Channel Strategies
    - 21.4.6.6.3. Product Strategies
- 21.4.7. AstraZeneca plc.
  - 21.4.7.1. Overview
  - 21.4.7.2. Product Portfolio
  - 21.4.7.3. Key Financials
  - 21.4.7.4. Sales Footprint
  - 21.4.7.5. SWOT Analysis
  - 21.4.7.6. Strategy Overview
    - 21.4.7.6.1. Marketing Strategies
    - 21.4.7.6.2. Channel Strategies
    - 21.4.7.6.3. Product Strategies
- 21.4.8. Lupin Limited
  - 21.4.8.1. Overview
  - 21.4.8.2. Product Portfolio
  - 21.4.8.3. Key Financials
  - 21.4.8.4. Sales Footprint
  - 21.4.8.5. SWOT Analysis
  - 21.4.8.6. Strategy Overview
    - 21.4.8.6.1. Marketing Strategies
    - 21.4.8.6.2. Channel Strategies
    - 21.4.8.6.3. Product Strategies
- 21.4.9. Dr Reddys Laboratories
  - 21.4.9.1. Overview
  - 21.4.9.2. Product Portfolio
  - 21.4.9.3. Key Financials
  - 21.4.9.4. Sales Footprint
  - 21.4.9.5. SWOT Analysis
  - 21.4.9.6. Strategy Overview
    - 21.4.9.6.1. Marketing Strategies
    - 21.4.9.6.2. Channel Strategies
    - 21.4.9.6.3. Product Strategies
- 21.4.10. Aurobindo Pharma Ltd
  - 21.4.10.1. Overview
  - 21.4.10.2. Product Portfolio
  - 21.4.10.3. Key Financials
  - 21.4.10.4. Sales Footprint
  - 21.4.10.5. SWOT Analysis
  - 21.4.10.6. Strategy Overview
    - 21.4.10.6.1. Marketing Strategies
    - 21.4.10.6.2. Channel Strategies
    - 21.4.10.6.3. Product Strategies
- 21.4.11. GSK plc.
  - 21.4.11.1. Overview
  - 21.4.11.2. Product Portfolio
  - 21.4.11.3. Key Financials
  - 21.4.11.4. Sales Footprint
  - 21.4.11.5. SWOT Analysis
  - 21.4.11.6. Strategy Overview
    - 21.4.11.6.1. Marketing Strategies
    - 21.4.11.6.2. Channel Strategies
    - 21.4.11.6.3. Product Strategies
- 21.4.12. Sun Pharmaceutical Industries Ltd.
  - 21.4.12.1. Overview
  - 21.4.12.2. Product Portfolio
  - 21.4.12.3. Key Financials
  - 21.4.12.4. Sales Footprint
  - 21.4.12.5. SWOT Analysis
  - 21.4.12.6. Strategy Overview
    - 21.4.12.6.1. Marketing Strategies
    - 21.4.12.6.2. Channel Strategies
    - 21.4.12.6.3. Product Strategies
- 21.4.13. Cipla ltd.
  - 21.4.13.1. Overview
  - 21.4.13.2. Product Portfolio
  - 21.4.13.3. Key Financials
  - 21.4.13.4. Sales Footprint
  - 21.4.13.5. SWOT Analysis
  - 21.4.13.6. Strategy Overview
    - 21.4.13.6.1. Marketing Strategies
    - 21.4.13.6.2. Channel Strategies
    - 21.4.13.6.3. Product Strategies

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 주요 시장 동향

제4장 부가가치 통찰

제5장 시장 배경

제6장 세계 시장 수요(10억 달러) 분석(2019-2024년) 및 예측(2025-2032년)

제7장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 약제별

제8장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 감염증별

제9장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 병원체별

제10장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 투여 경로별

제11장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 유통 채널별

제12장 세계의 인공관절 감염증 치료 시장 분석(2019-2024년) 및 예측(2025-2032년), 지역별

제13장 북미 시장 분석(2019-2024년) 및 예측(2025-2032년)

제14장 라틴아메리카 시장 분석(2019-2024년) 및 예측(2025-2032년)

제15장 유럽 시장 분석(2019-2024년) 및 예측(2025-2032년)

제16장 동아시아 시장 분석(2019-2024년) 및 예측(2025-2032년)

제17장 남아시아 시장 분석(2019-2024년) 및 예측(2025-2032년)

제18장 오세아니아 시장 분석(2019-2024년) 및 예측(2025-2032년)

제19장 중동 및 아프리카 시장 분석(2019-2024년) 및 예측(2025-2032년)

제20장 시장 구조 분석

제21장 경쟁 분석